Major Depressive Disorder (MDD)
Pipeline by Development Stage
On Market (2)
Approved therapies currently available
Competitive Landscape
10 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (13)
Total enrollment: 9,048 patients across 13 trials
A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
Expanded Access to Fosigotifator
Non-invasive Brain Stimulation in Subjects with Major Depressive Disorder
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
European Drug Utilization Study
Retrospective TMS Therapy for Adults With MDD